Comparison of the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants: a prospective randomized double-blind controlled trial
HE Ting, LIAO Zheng-Chang, DING Ying, WANG Ming-Jie, LI Wen, GAN Ji-Min, YUE Shao-Jie
Department of Neonatology, Xiangya Hospital, Central South University, Changsha 410008, China
Abstract：Objective To compare the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants. Methods A total of 98 preterm infants with a gestational age of 28- < 34 weeks between April 2018 and December 2019 were enrolled. They were randomly administered with domestic (n=48) or imported caffeine citrate (n=50) within 6 hours after birth. The therapeutic effects, complications, adverse effects and clinical outcomes were compared between the two groups. Results There were no significant differences in the incidence of apnea within 7 days after birth, daily frequency of apnea, the time of apnea disappearance, the failure rate of intubation-surfactant-extubation strategy, the time of non-invasive assisted ventilation, the duration of oxygen therapy, the duration of caffeine citrate therapy, the length of hospital stay, blood gas analysis results, liver and kidney function testing results between the two groups (P > 0.05). There were no significant differences in the incidence of complications and the mortality rate between the two groups (P > 0.05). There was no significant difference in the incidence of adverse effects between the two groups (P > 0.05). Conclusions The efficacy and safety of domestic caffeine citrate in the treatment of apnea are similar to those of imported caffeine citrate in preterm infants.
HE Ting,LIAO Zheng-Chang,DING Ying et al. Comparison of the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants: a prospective randomized double-blind controlled trial[J]. CJCP, 2020, 22(7): 684-689.
Vatlach S, Arand J, Engel C, et al. Safety profile comparison between extemporaneous and a licensed preparation of caffeine citrate in preterm infants with apnea of prematurity[J]. Neonatology, 2014, 105(2):108-111.
Kua KP, Lee SW. Systematic review and meta-analysis of clinical outcomes of early caffeine therapy in preterm neonates[J]. Br J Clin Pharmacol, 2017, 83(1):180-191.
Zubrow AB, Hulman S, Kushner H, et al. Determinants of blood pressure in infants admitted to neonatal intensive care units:a prospective multicenter study. Philadelphia Neonatal Blood Pressure Study Group[J]. J Perinatol, 1995, 15(6):470-479.
[9]
Dani C, Corsini I, Poggi C. Risk factors for intubation-surfactant-extubation (INSURE) failure and multiple INSURE strategy in preterm infants[J]. Early Hum Dev, 2012, 88 Suppl 1:S3-S4.
[10]
Lucchini R, Bizzarri B, Giampietro S, et al. Feeding intolerance in preterm infants. How to understand the warning signs[J]. J Matern Fetal Neonatal Med, 2011, 24 Suppl 1:72-74.
[11]
Eichenwald EC, Committee on fetus and newborn, American Academy of Pediatrics. Apnea of prematurity[J]. Pediatrics, 2016, 137(1):e20153757.
[12]
Henderson-Smart DJ. The effect of gestational age on the incidence and duration of recurrent apnoea in newborn babies[J]. Aust Paediatr J, 1981, 17(4):273-276.
[13]
Aranda JV, Gorman W, Bergsteinsson H, et al. Efficacy of caffeine in treatment of apnea in the low-birth-weight infant[J]. J Pediatr, 1977, 90(3):467-472.
[14]
Vliegenthart R, Miedema M, Hutten GJ, et al. High versus standard dose caffeine for apnoea:a systematic review[J]. Arch Dis Child Fetal Neonatal Ed, 2018, 103(6):F523-F529.
[15]
Ravichandran S, Chouthai NS, Patel B, et al. Higher daily doses of caffeine lowered the incidence of moderate to severe neurodevelopmental disabilities in very low birth weight infants[J]. Acta Paediatr, 2019, 108(3):430-435.
[16]
Lodha A, Seshia M, McMillan DD, et al. Association of early caffeine administration and neonatal outcomes in very preterm neonates[J]. JAMA Pediatr, 2015, 169(1):33-38.
[17]
Taha D, Kirkby S, Nawab U, et al. Early caffeine therapy for prevention of bronchopulmonary dysplasia in preterm infants[J]. J Matern Fetal Neonatal Med, 2014, 27(16):1698-1702.
[18]
Dobson NR, Patel RM, Smith PB, et al. Trends in caffeine use and association between clinical outcomes and timing of therapy in very low birth weight infants[J]. J Pediatr, 2014, 164(5):992-998.e3.
[19]
Steer P, Flenady V, Shearman A, et al. High dose caffeine citrate for extubation of preterm infants:a randomised controlled trial[J]. Arch Dis Child Fetal Neonatal Ed, 2004, 89(6):F499-F503.
[20]
Schmidt B, Roberts RS, Davis P, et al. Long-term effects of caffeine therapy for apnea of prematurity[J]. N Engl J Med, 2007, 357(19):1893-1902.
[21]
Moschino L, Zivanovic S, Hartley C, et al. Caffeine in preterm infants:where are we in 2020?[J]. ERJ Open Res, 2020, 6:00330-2019.
[22]
Schmidt B, Anderson PJ, Doyle LW, et al. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity[J]. JAMA, 2012, 307(3):275-282.
[23]
Harer MW, Askenazi DJ, Boohaker LJ, et al. Association between early caffeine citrate administration and risk of acute kidney injury in preterm neonates:results from the AWAKEN study[J]. JAMA Pediatr, 2018, 172(6):e180322.
[24]
Chen J, Jin L, Chen X. Efficacy and safety of different maintenance doses of caffeine citrate for treatment of apnea in premature infants:a systematic review and meta-analysis[J]. Biomed Res Int, 2018, 2018:9061234.
[25]
Shrestha B, Jawa G. Caffeine citrate-is it a silver bullet in neonatology?[J]. Pediatr Neonatol, 2017, 58(5):391-397.
[26]
Stevenson DK. On the caffeination of prematurity[J]. N Engl J Med, 2007, 357(19):1967-1968.
[27]
Bauer J, Maier K, Linderkamp O, et al. Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea[J]. Pediatrics, 2001, 107(4):660-663.
